MERCURI-2 (2026) — Trial Summary
MERCURI-2 (2026): Multicenter, double-blind, placebo-controlled randomized trial in the Netherlands (2 academic + 5 nonacademic hospitals) of dapagliflozin 10 mg once daily versus placebo for four doses starting the day before elective cardiac surgery through postoperative day 2 (NCT05590143). Prima
References
- Oosterom-Eijmael MJP, Hulst AH, de Oliveira NPM, et al; MERCURI-2 Study Group. Dapagliflozin and Acute Kidney Injury Following Cardiac Surgery: A Randomized Clinical Trial. JAMA. 2026;336(9):765-773.